XML 68 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Variable Interest Entities (Details) (USD $)
 3 Months Ended 6 Months Ended 0 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Jun. 30, 2013
Dec. 31, 2012
Jun. 30, 2014
Viking
Jun. 30, 2014
Viking
program
Jul. 01, 2014
Viking
Subsequent Event
May 21, 2014
Debt
May 21, 2014
Debt
Viking
Variable Interest Entity [Line Items]                  
Number of programs licensed           5      
Convertible loan facility         $ 1,300,000 $ 1,300,000     $ 2,500,000
Interest accrual rate, less than               5.00%  
Repayment percentage               200.00%  
Threshold Proceeds from IPO             45,000,000    
Value of common stock issued upon IPO             29,000,000    
Threshold proceeds from private financing             20,000,000    
Cash and cash equivalents 14,537,000 11,639,000 5,923,000 12,381,000 891,000 891,000      
Other current assets 1,123,000 959,000     28,000 28,000      
Capitalized IPO expenses, Viking Therapeutics, Inc. 1,094,000 0     1,094,000 1,094,000      
Total current assets 28,585,000 24,881,000     2,013,000 2,013,000      
Other assets 253,000 299,000     1,000 1,000      
Total assets 99,847,000 104,713,000     2,014,000 2,014,000      
Accounts payable 5,059,000 3,951,000     1,416,000 1,416,000      
Accrued liabilities 3,241,000 5,337,000     52,000 52,000      
Current portion of note payable 2,698,000 9,109,000     345,000 345,000      
Total current liabilities 18,621,000 28,939,000     1,813,000 1,813,000      
Long-term portion of notes payable         1,285,000 1,285,000      
Total liabilities $ 36,761,000 $ 55,100,000     $ 3,098,000 $ 3,098,000      
Loss percentage recorded           100.00%